Literature DB >> 1727499

Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.

H G Kräusslich1.   

Abstract

The active form of the retroviral proteinase (PR) is a homodimer of monomeric subunits expressed as integral parts of the viral gag-pol precursor polyproteins, and dimerization of polyproteins is presumed to be important for regulation of PR activity. Expression of a single-chain dimer of the human immunodeficiency virus (HIV) type 1 PR as a component of the viral polyprotein has been shown to prevent particle assembly and viral infectivity (H.-G. Kräusslich, Proc. Natl. Acad. Sci. USA 88:3213-3217, 1991). Ro31-8959, a specific inhibitor of HIV PR, blocked proteolysis of polyproteins containing either wild-type or single-chain dimer PR at the same inhibitor concentration. Different inhibitor concentrations gave three phenotypic effects for the linked PR: at a concentration of 10 nM, cytotoxicity was prevented yet viral polyproteins were almost completely processed and no particles were released. The majority of HIV capsid proteins was found in the soluble cytoplasmic fraction, whereas at a concentration of 1 microM inhibitor most HIV gag proteins were associated with an insoluble fraction. Release of particles consisting of partially processed polyproteins was observed at 100 nM Ro31-8959, and polyprotein processing was blocked at 10 microM. Particles derived from the dimer-containing provirus were noninfectious independently of the inhibitor concentration. Production of infectious HIV after transfection of wild-type provirus was abolished at 100 nM and markedly reduced at 10 nM Ro31-8959.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727499      PMCID: PMC238318     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  Viral proteinases: weakness in strength.

Authors:  J Kay; B M Dunn
Journal:  Biochim Biophys Acta       Date:  1990-01-30

Review 2.  Viral proteinases.

Authors:  H G Kräusslich; E Wimmer
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region.

Authors:  M Hadzopoulou-Cladaras; B K Felber; C Cladaras; A Athanassopoulos; A Tse; G N Pavlakis
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.

Authors:  T J McQuade; A G Tomasselli; L Liu; V Karacostas; B Moss; T K Sawyer; R L Heinrikson; W G Tarpley
Journal:  Science       Date:  1990-01-26       Impact factor: 47.728

7.  Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.

Authors:  T D Meek; D M Lambert; G B Dreyer; T J Carr; T A Tomaszek; M L Moore; J E Strickler; C Debouck; L J Hyland; T J Matthews
Journal:  Nature       Date:  1990-01-04       Impact factor: 49.962

8.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus.

Authors:  D Trono; M B Feinberg; D Baltimore
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

9.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.

Authors:  R L Shoeman; B Höner; T J Stoller; C Kesselmeier; M C Miedel; P Traub; M C Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

10.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.

Authors:  J Erickson; D J Neidhart; J VanDrie; D J Kempf; X C Wang; D W Norbeck; J J Plattner; J W Rittenhouse; M Turon; N Wideburg
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

View more
  14 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

3.  Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases.

Authors:  G S Laco; M C Fitzgerald; G M Morris; A J Olson; S B Kent; J H Elder
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Plasma membrane targeting of chimeric intracisternal A-type particle polyproteins leads to particle release and specific activation of the viral proteinase.

Authors:  R Welker; A Janetzko; H G Krausslich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

Authors:  Dirk Jochmans; Maria Anders; Inge Keuleers; Liesbeth Smeulders; Hans-Georg Kräusslich; Günter Kraus; Barbara Müller
Journal:  Retrovirology       Date:  2010-10-15       Impact factor: 4.602

9.  Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions.

Authors:  D A Davis; K Yusa; L A Gillim; F M Newcomb; H Mitsuya; R Yarchoan
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  The nucleocapsid region of human immunodeficiency virus type 1 Gag assists in the coordination of assembly and Gag processing: role for RNA-Gag binding in the early stages of assembly.

Authors:  David E Ott; Lori V Coren; Teresa Shatzer
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.